We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

Proficio Capital Partners LLC bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) during ...

Morgan Stanley assumed coverage of Neurocrine (NBIX) with an Overweight rating and a price target of $150, down from $185. The firm sees ...

However, recent mixed results from other pipeline candidates have raised questions about the company's ability to successfully bring new products to market beyond Ingrezza. Neurocrine's strategy ...

Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) was upgraded by research analysts at StockNews.com from a “buy” rating ...

However, recent mixed results from other pipeline candidates have raised questions about the company's ability to successfully bring new products to market beyond Ingrezza. Neurocrine's strategy ...

Neurocrine Biosciences (NasdaqGS:NBIX) announced the initiation of a Phase 1 clinical study for the compound NBI-1140675, a new VMAT2 inhibitor. This development could influence investor sentiment, ...

SAN DIEGO, Feb. 21, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that its Board of Directors has authorized a new share repurchase program under which ...

SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences ... We sell different types of products and services to both investment professionals and individual investors.

About Neurocrine Biosciences Neurocrine Biosciences ... risks related to the development of our product candidates; risks associated with our dependence on third parties for development ...